The Immune Monitoring Shared Resource (IMSR) provides (1) state-of-the-art immunoassays to allow NCCC clinicians to monitor the immune responses of patients enrolled in clinical trials;(2) quality control and quality assurance, including validation of the reproducibility of the result;(3) expert guidance in the choice and interpretation of immunoassays most relevant to a particular study or clinical trial;and (4) a resource for all NCCC Investigators and the Dartmouth community to use dedicated instruments not normally available in individual laboratories?e.g., ELISPOT reader, autoMACS, Robosep, Luminex. In 2005, the IMSR began a process of Proficiency Testing through membership in the Cancer Vaccine Consortium, and that has continued. Initial participation was in the ELISPOT panel, and, in 2007, participation was extended for the first time to pentamer-staining. The total operating budget for FY 2007 was $365,161, with total chargebacks of $109,773 requiring $255,388 in non-chargeback subvention, derived from a combination of the NCCC CCSG and Institutional resources. There is strong institutional support for this Shared Resource that comes from Dartmouth Medical School, from the NIH-NCRR COBRE Immunology/Inflammation Program Project, the Immunotherapy Center, the Department of Microbiology and Immunology, and the Department of Neurology. NCCC provided $66,603 or 26% of this non-chargeback subvention. We are requesting a budget of $117,498 from the NCCC CCSG for the first year of the competitive renewal, representing a more proportionate level than current support, approximately 45% of the non-chargeback subvention needed to support. The IMSR currently provides 18 NCCC members and their laboratories with services valued at $52,708 in chargebacks for FY 2007. NCCC members represent 72% of the total laboratories using this facility at Dartmouth. They used 61% of the services rendered, and that usage constitutes 48% of the total chargeback fees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023108-35S3
Application #
8787218
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
35
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
City
Hanover
State
NH
Country
United States
Zip Code
03755
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Bronson, Mackenzie R; Kapadia, Nirav S; Austin, Andrea M et al. (2018) Leveraging Linkage of Cohort Studies With Administrative Claims Data to Identify Individuals With Cancer. Med Care 56:e83-e89
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Hancock, D B; Guo, Y; Reginsson, G W et al. (2018) Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. Mol Psychiatry 23:1-9
Li, Yafang; Xiao, Xiangjun; Han, Younghun et al. (2018) Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis 39:336-346
Gorlov, Ivan; Orlow, Irene; Ringelberg, Carol et al. (2018) Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics. Melanoma Res 28:380-389
Shiner, Brian; Westgate, Christine Leonard; Gui, Jiang et al. (2018) A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice. J Clin Psychiatry 79:
Wu, Wenting; 23andMe Research Team; Amos, Christopher I et al. (2018) Inverse Relationship between Vitiligo-Related Genes and Skin Cancer Risk. J Invest Dermatol 138:2072-2075
Downey-Kopyscinski, Sondra; Daily, Ellen W; Gautier, Marc et al. (2018) An inhibitor of proteasome ?2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv 2:2443-2451
Varn, Frederick S; Tafe, Laura J; Amos, Christopher I et al. (2018) Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. Oncoimmunology 7:e1431084

Showing the most recent 10 out of 1911 publications